Latest News
Digital Twinning, and how EdgeTI (CTRL.V) is a serious story you’ve never heard of
Bionxt Solutions (BNXT.C): Seeking to confirm national-level cancer drug patent
Why Prospera Energy (PEI.V) might be a transformational investment opportunity in Canadian oil & gas
Sparc AI (SPAI.C) completes development of drone advanced target acquisition system
Plurilock (PLUR.V) lands $19 million deal, largest in their history
Rex Resources (OWN.V) continues gearing up with BC gold property
Biotech Sector Roundup – Investor Roundtable Video
Welcome to Equity.Guru’s Roundtable where our writers weigh in on the pros and cons of a spotlight company, break out where they see value, and help you avoid public markets pitfalls.
Today, we focus on the biotech sector and discuss three interesting companies: Kezar Life Sciences (KZR.Q), BioMarin Pharmaceutical (BMRN.Q) and Medexus Pharmaceutical (MDP.T).
Enjoy!
Related Posts
Potential of Medexus Pharmaceuticals: Chris Parry gets into what investors are missing
Medexus Pharma (MDP.TO) Breaks Records: A Deep Dive into Quarterly Earnings, Portfolio Growth, and Future Opportunities
Medexus Pharmaceuticals (MDP): A Roller Coaster Ride to Success
Medexus Pharmaceuticals Sets New Revenue Records and Continues Expansion with Innovative Products and Financing
Medexus Pharmaceuticals (MDP.T) deals with its debentures
Medexus CEO (MDP.T) on creating Canada’s specialty pharma success story
More on BMRN.Q, KZR.Q, MDP.T
Analysts say this specialty pharma stock is on track for a record $100 million USD 2023
This specialty pharma stock trades at one-third of annual revenue, is it time to buy?
Medexus Pharma (MDP.T) ripping it up as quarterly financials loom – Chris Parry’s Daily Rant
Medexus Pharmaceuticals (MDP.T) – The Gauntlet with Chris Parry
FDA info request, treosulfan and how the market should react to Medexus – Chris Parry’s Daily Rant Video
Medexus Pharmaceuticals (MDP.T) CEO picks up the gauntlet